CLINICAL EFFICACY OF SPARFLOXACIN IN MYCOPLASMAL PNEUMONIA - A PILOT-STUDY

Sparfloxacin, a new synthetic quinolone antimicrobial agent, was admin istered to 20 patients with mycoplasmal pneumonia to evaluate its clin ical efficacy and adverse effects. The efficacy rate was 100%. In all cases, the subjective symptoms, chest x-ray findings and inflammatory response improved within 5 days after sparfloxacin administration. The re were no adverse events including abnormal laboratory values in any of the patients during the treatment period, and no adverse effects th at were thought to be due to sparfloxacin were encountered. Since spar floxacin displays an excellent activity against Mycoplasma pneumoniae and has a broad spectrum of antimicrobial activity against not only Gr am-negative bacteria but also Gram-positive bacteria, Legionella, Chla mydia and acid-fast bacteria, it appears to be useful as the drug of f irst choice in the treatment of respiratory tract infections.